Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F7VA7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,527
Award facts
- Contract value 100% obligated
- $13,526.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,526.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 300 mg/2 mL Dupixent pens on January 12, 2026, with an ultimate completion date of January 13, 2026. This contract carries no set-aside designation and represents a competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s existing Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive $999.99 billion pharmaceutical supply vehicle valued through December 2031 that enables delivery of specialty medications, brand-name and generic drugs, vaccines, and related medical supplies to support military healthcare programs globally.
AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and related entities. The company's federal contract portfolio demonstrates extensive experience delivering a wide range of therapeutic medications across multiple domains. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions such as moderate-to-severe eczema, asthma, and chronic rhinosinusitis with nasal polyps, representing the type of specialized pharmaceutical product the company routinely provides to support military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F7VA7?
SPE2DR26F7VA7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F7VA7 worth?
The government has obligated $13,527 on SPE2DR26F7VA7.
Is contract SPE2DR26F7VA7 an order under another contract?
Yes. SPE2DR26F7VA7 is a delivery order under SPE2DR25D2216, an indefinite delivery contract.
Was contract SPE2DR26F7VA7 competed?
The extent of competition for SPE2DR26F7VA7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award